Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Gossamer Bio, Inc.GOSS · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $172.2M[1]
Standard universeinsiderevenue above $1M and assets above $10M[1-2]
Warningsshort runway, thin data · fortress balance sheet
Inputs computable6 of 14
Graded fromfilings received through Mar 17, 2026206 days before the rescan; every figure keyed to the SEC receipt date
Last close$9.722026-10-08; market equity $4.8B; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$10NovDecJanFebMarAprMayJunJulAugSepOct$9.88
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2020nonen/aQ3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 17, 2026; the document on sec.gov.

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH associated with interstitial lung disease, or PH-ILD. Our goal is to be an industry leader in, and to enhance the lives of patients living with, PH. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world.

Warnings [top]

Short runway. cash runway is 3.0 months[3]
Thin data. 6 of 14 grade factors are computable; minimum is 7
Fortress balance sheet. cash minus debt is 106,567,000 USD; Altman Z is not used[4-5]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 82.0
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
a prior annual debt, equity, and cash observation is required
Accruals ratio0.4%[1,6-8](6.6%)82.08112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 68.5
Twelve-month failure probability0.13%0.07%64.02482026-06-30
Altman Z double-prime(30.36)[1,9-14](0.31)80.47562025-12-31
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio2.64x[9-10]2.96x61.18392025-12-31
Growth and financing, sleeve percentile 56.9
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 2
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years(14.2%)[1,8,15-16]2.1%74.57042025-12-31
Net share issuance, one year3.3%[17-18]2.5%39.36342026-03-10

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month417.1%8.0%99hotter than 99 of 100 peers
Distance from 52-week high(39.6%)(31.4%)39closer to its high than 39 of 100 peers
EBIT to enterprise value(3.5%)(1.5%)45pricier than 55 of 100 peers
Free cash flow yield(3.5%)(1.0%)44pricier than 56 of 100 peers
Book value to price(0.02)0.2810pricier than 90 of 100 peers
Sales to price0.010.316pricier than 94 of 100 peers
Composite equity issuance, five years186.8%20.3%88more equity-funded than 88 of 100 peers
Relative strength against the sector, log excess return1.43(0.14)99ahead of 99 of 100 peers

Inputs: market equity $4.8B; EBIT -$170.7M; free cash flow -$171.3M; book equity -$94.0M; sales $48.5M; debt $28.5M; cash $41.1M[19].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(54.0%)✗ fail[6,8]
Operating cash flow above zero-$171.3M✗ fail[7]
Return on assets improved(35.9 pts)✗ fail[6,8,15,20]
Operating cash flow exceeds net income-$896,000✗ fail[6-7]
Long-term leverage felln/a[1,8,15,21]
Current ratio improved(424.2 pts)✗ fail[9-10,22-23]
No new shares issued3.3%✗ fail[17-18]
Gross margin improvedn/a
Asset turnover improved(21.4 pts)✗ fail[2,8,15,24]
Cash, filings, liquidity
Cash and equivalents$41.1M[3]
Operating cash flow, four quarters-$162.6M[3,7,25-28]
Months of runway3.0
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing57
10-Q received Aug 13, 2026
Median daily dollar volume$2.7M
63 sessions
Days since newest grade input206

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$172.2M2025-12-312026-03-1710-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$48.5M2025-12-312026-03-1710-Kfiling · viewer · series
3cashus-gaap:CashAndCashEquivalentsAtCarryingValue$41.1M2026-06-302026-08-1310-Qfiling · viewer · series
4cashus-gaap:CashAndCashEquivalentsAtCarryingValue$135.0M2019-12-312021-02-2610-Kfiling · viewer · series
5total debtus-gaap:LongTermDebt$28.5M2019-12-312020-03-2410-Kfiling · viewer · series
6net incomeus-gaap:NetIncomeLoss-$170.4M2025-12-312026-03-1710-Kfiling · viewer · series
7operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$171.3M2025-12-312026-03-1710-Kfiling · viewer · series
8assetsus-gaap:Assets$315.3M2024-12-312026-03-1710-Kfiling · viewer · series
9current assetsus-gaap:AssetsCurrent$167.6M2025-12-312026-03-1710-Kfiling · viewer · series
10current liabilitiesus-gaap:LiabilitiesCurrent$63.4M2025-12-312026-03-1710-Kfiling · viewer · series
11retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$1.4B2025-12-312026-03-1710-Kfiling · viewer · series
12operating incomeus-gaap:OperatingIncomeLoss-$170.7M2025-12-312026-03-1710-Kfiling · viewer · series
13book equityus-gaap:StockholdersEquity-$122.8M2025-12-312026-03-1710-Kfiling · viewer · series
14liabilitiesus-gaap:Liabilities$295.0M2025-12-312026-03-1710-Kfiling · viewer · series
15assetsus-gaap:Assets$311.9M2023-12-312025-03-1310-Kfiling · viewer · series
16assetsus-gaap:Assets$272.4M2022-12-312024-03-0510-Kfiling · viewer · series
17shares outstandingdei:EntityCommonStockSharesOutstanding234,696,2812026-03-102026-03-1710-Kfiling · viewer · series
18shares outstandingdei:EntityCommonStockSharesOutstanding227,221,2612025-03-062025-03-1310-Kfiling · viewer · series
19shares outstandingdei:EntityCommonStockSharesOutstanding488,846,7222026-08-082026-08-1310-Qfiling · viewer · series
20net incomeus-gaap:NetIncomeLoss-$56.5M2024-12-312026-03-1710-Kfiling · viewer · series
21long term debtus-gaap:LongTermDebtNoncurrent$02024-12-312025-03-1310-Kfiling · viewer · series
22current assetsus-gaap:AssetsCurrent$309.9M2024-12-312026-03-1710-Kfiling · viewer · series
23current liabilitiesus-gaap:LiabilitiesCurrent$45.0M2024-12-312026-03-1710-Kfiling · viewer · series
24revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$114.7M2024-12-312026-03-1710-Kfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$78.1M2026-06-302026-08-1310-Qfiling · viewer · series
26operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$38.7M2026-03-312026-05-1510-Qfiling · viewer · series
27operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$123.0M2025-09-302025-11-0510-Qfiling · viewer · series
28operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$86.8M2025-06-302026-08-1310-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.